<SEC-DOCUMENT>0001437749-22-028487.txt : 20221206
<SEC-HEADER>0001437749-22-028487.hdr.sgml : 20221206
<ACCEPTANCE-DATETIME>20221205215857
ACCESSION NUMBER:		0001437749-22-028487
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221205
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221206
DATE AS OF CHANGE:		20221205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		221446577

	BUSINESS ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20221205_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dffn="http://www.dffn.com/20221205"><head>
	<title>dffn20221205_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 12/6/2022 2:06:33 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20228K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20228K" name="dei:EntityCentralIndexKey">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dffn-20221205.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20228K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-12-05</xbrli:startDate>
<xbrli:endDate>2022-12-05</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<div style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20228K" name="dei:DocumentType"><b><b>8-K</b></b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d) of</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>the Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b><b>December 5, 2022</b></b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityRegistrantName"><b>DIFFUSION PHARMACEUTICALS INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityFileNumber"><b>000-24477</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityTaxIdentificationNumber"><b>30-0645032</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation)</div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number)</div>
			</td>
			<td style="vertical-align:top;width:33.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align:top;width:50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine1"><b>300 East Main Street, Suite 201</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressCityOrTown"><b>Charlottesville</b></ix:nonNumeric><b>, <ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b><b>Virginia</b></b></ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressPostalZipCode"><b>22902</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices)</div>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Zip Code)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20228K" name="dei:CityAreaCode"><b><b>434</b></b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20228K" name="dei:LocalPhoneNumber"><b><b>220-0718</b></b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9746;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 42.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title of each class</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 24.6%; border-top: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Trading Symbol(s)</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33.7%; border-top: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 42.8%; border-left: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 24.6%; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:TradingSymbol">DFFN</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33.7%; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</b>&#167;&#8201;<b>230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</b>&#167;&#8201;<b>240.12b-2 of this chapter).</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Emerging growth company</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#9744;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01 </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Other Events</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On December 5, 2022, Diffusion Pharmaceuticals Inc. issued a press release announcing the issuance of a letter to its stockholders. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&#xa0;<b>9.01</b>&#xa0;&#8211;&#xa0;<b>Financial Statements and Exhibits</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(d) Exhibits</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:58.2761437908497%;margin-left:0pt;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Number</b></div>
			</td>
			<td style="vertical-align:top;width:90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:10%;">&#xa0;</td>
			<td style="vertical-align:middle;width:90%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align:top;width:90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_453243.htm" style="-sec-extract:exhibit;">Press Release, issued December 5, 2022</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">&#xa0;</td>
			<td style="vertical-align:top;width:90%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tbody><tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Dated: December 5, 2022</div>
			</td>
			<td colspan="2" style="width: 38%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b>DIFFUSION PHARMACEUTICALS INC.</b></div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 35%; width: 33%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; width: 33%;" valign="bottom">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
		</tr>
		<tr>
			<td align="left" style="width: 50%; text-align: left; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 3%; text-align: left; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </span></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&#xa0;</span>William Elder</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Name:</div>
			</td>
			<td style="width: 35%; width: 33%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">William Elder</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 50%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
			<td style="width: 3%; width: 5%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Title:</div>
			</td>
			<td style="width: 35%; width: 33%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">General Counsel &amp; Corporate Secretary</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_453243.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_453243.htm</title>

	<!-- Generated by ThunderDome Portal - 12/6/2022 12:40:21 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci</b>&#8217;<b>s History of Stockholder Value Destruction and Self-Dealing</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process </i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Diffusion received bids from more than 15 companies participating in review process</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>LifeSci invited to participate in review process on same terms as all other bidders following submission of client</i>&#8217;<i>s unsolicited offer, but LifeSci instead chose to launch a proxy contest against our highly qualified board</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>LifeSci</i>&#8217;<i>s track record demonstrates a highly troubling pattern of self-dealing and stockholder value destruction, including more than $1.3 billion of stockholder losses in recent SPAC transactions</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Diffusion</i>&#8217;<i>s board and management are fully committed to maximizing value for all stockholders through the completion of the strategic review process, notwithstanding LifeSci</i>&#8217;<i>s self-serving attempts to disrupt the process</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Diffusion urges stockholders to vote </i>&#8220;<i>FOR</i>&#8221;<i>&nbsp;each of the Board</i>&#8217;<i>s six nominees for director on your WHITE proxy card</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CHARLOTTESVILLE, Va., December 5, 2022 -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing novel therapies that may enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most, today sent a letter to its stockholders. The letter highlights the strength, experience and quality of the Company&#8217;s board of directors as it continues to take steps to unlock stockholder value through a strategic review process. The letter also summarizes the value-destructive acquisition offer presented by LifeSci Capital on behalf of a purported client, the dismal track record of LifeSci Capital and its many affiliates in the biopharmaceutical space, and LifeSci-affiliated funds&#8217; recent nomination of an unqualified dissident slate of nominees for election as directors at the Company&#8217;s 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Diffusion</b>&#8217;<b>s board of directors urges stockholders to vote </b>&#8220;<b>FOR</b>&#8221;<b> each of its six nominees for director on your WHITE proxy card</b>. The Annual Meeting will be held virtually on December 30, 2022, at 8:00 a.m., Eastern Time. Stockholders of record as of the close of business on November 1, 2022, are entitled to vote at the meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s proxy statement and other important information related to the Annual Meeting can be found at investors.diffusionpharma.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The full text of the letter follows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:90pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">December 5, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dear Fellow Stockholder, </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The value of your investment is at stake at Diffusion&#8217;s 2022 Annual Meeting of Stockholders, which will be held on December 30, 2022. LifeSci Special Opportunities Master Fund Ltd. (&#8220;LifeSci Master Fund&#8221;), a fund affiliated with the investment bank LifeSci Capital, on behalf of itself and other related entities (collectively with their respective affiliates, &#8220;LifeSci&#8221;), and managed by David Dobkin, the LifeSci Capital banker who previously delivered an unsolicited, lowball offer to the Company on behalf of a purported client, is seeking to replace our board of directors (the &#8220;Board&#8221;) with its hand-picked, inferior and unqualified slate of nominees. In contrast to LifeSci&#8217;s nominees, our Board has the required skills and expertise to drive our strategy forward through its ongoing evaluation of a range of value-creating opportunities as part of our strategic review process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIFFUSION</b>&#8217;<b>S BOARD IS DILIGENTLY ADVANCING THE STRATEGIC REVIEW PROCESS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board has made significant progress to date in its strategic review of opportunities to enhance value for all stockholders. Working together with our financial advisor, Canaccord Genuity LLC, and legal advisor, Dechert LLP, our Board has been driving a thorough process. We received bids from more than 15 companies, and we are currently in the process of identifying and negotiating the most compelling, value-enhancing transaction for <b>ALL</b> Diffusion stockholders. While we cannot provide any assurance as to the ultimate outcome of this strategic review process, we are very encouraged by the level of response received from interested parties. Our Board and management team are highly motivated to complete this process expeditiously and bring an attractive opportunity to our stockholders as soon as possible within a reasonable timeframe.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIFFUSION</b>&#8217;<b>S BOARD IS LEVERAGING RELEVANT EXPERIENCE IN CONDUCTING THE STRATEGIC REVIEW</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board is currently composed of uniquely qualified leaders with public company senior leadership experience, including at the C-level in Fortune 50 companies. A majority of our directors are independent, and multiple directors &#8211; including our Board Chair and our Chief Executive Officer -- have been added to the Board since the beginning of 2020. During this same timeframe, our Board has also overseen significant changes to our management team, with four of our five current executive officers appointed to their position since September 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board is highly engaged and actively overseeing the strategic review process. Stockholders should not be misled by LifeSci&#8217;s claims and self-serving campaign: this is <b>NOT</b> a board that is entrenching itself. To the contrary, the Board is diligently reviewing a range of potential transactions that will likely involve significant changes in the composition of the Board, including a sale of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current directors have a broad industry network and a deep understanding of pharmaceutical dealmaking that will be key to negotiating a transaction that maximizes value for <b>ALL</b> stockholders, and our board&#8217;s experience has been invaluable in carefully evaluating the proposals received from interested parties to date. Furthermore, unlike the destructive and conflict-riddled special purpose acquisition company (&#8220;SPAC&#8221;) mergers led by LifeSci in recent years that are described below, our Board is being advised on this process by a highly qualified team of independent financial, legal and other advisors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci&#8217;s nominees on the other hand, with their resumes in the ammunitions industry, lobbying and private consulting, SPACs or solar technology &#8211; as well as various affiliations with LifeSci and its principals &#8211; lack any relevant industry relationships, knowledge or experience that could credibly generate any value for stockholders or pursue anything other than advancing LifeSci&#8217;s self-serving agenda.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Particularly given the poor quality of LifeSci&#8217;s nominees, as well as LifeSci&#8217;s questionable motives and misleading statements in its past dealings with the Company, we believe any changes to our Board at this critical juncture threaten to seriously jeopardize the progress and momentum of the ongoing strategic review process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LIFESCI HAS A TROUBLING HISTORY OF STOCKHOLDER VALUE DESTRUCTION AND SELF-DEALING</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci is a nebulous organization with a dismal track record in the public biopharmaceutical space. Its motivations and actions are highly unorthodox and laden with conflicts of interest. In contrast to the Board&#8217;s strategic review, we can only guess how LifeSci&#8217;s actions are intended to generate value for Diffusion&#8217;s other stockholders, as they have yet to surface any credible proposal, only opaque and ever-changing half-truths regarding their intentions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For example, LifeSci misled Diffusion&#8217;s management team throughout the parties&#8217; correspondence. It first indicated that it was a LifeSci client (rather than <b>LifeSci itself</b>) that was acquiring a position in our stock, then presented Diffusion with an unsolicited, lowball acquisition offer purportedly on behalf of a client, only to turn around and nominate a slate of inexperienced director nominees on its own behalf while the company is in the middle of a strategic review, a process in which &#8211; despite its earlier requests that Diffusion consider certain unnamed strategic alternatives with one of its clients -- LifeSci has refused to allow its purported client to participate. In fact, the same company on behalf of which LifeSci purportedly submitted the unsolicited offer subsequently approached Diffusion <b>through a different investment bank</b> about potentially participating in the Company&#8217;s process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci&#8217;s public statements regarding Diffusion have been equally confusing and misleading. For example, among other misrepresentations in LifeSci&#8217;s recently filed preliminary proxy statement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci claims that Mr. Dobkin&#8217;s outreach to Diffusion on May 26, 2022 was on behalf of, &#8220;an unaffiliated client.&#8221;&nbsp;&nbsp;However, in Mr. Dobkin&#8217;s e-mail to management, he stated that his outreach was on behalf of, &#8220;one of your larger shareholders.&#8221;&nbsp;Based on LifeSci Master Fund&#8217;s transaction history, it appears this &#8220;client&#8221;&nbsp;was not an unaffiliated entity at all, but rather <b>LifeSci itself</b>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci claims that the intent of its outreach was to encourage Diffusion to undertake a review of certain strategic alternatives. However, Diffusion was already engaged in just such a process at the time of LifeSci&#8217;s outreach, has publicly reported its significant progress in that process over the ensuing months, and has invited LifeSci&#8217;s clients to participate in a competitive bid process on numerous occasions. Despite this, LifeSci declined to participate in the process and instead made the decision to nominate an alternate slate of directors on its own behalf without any further rationale.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci claims that Diffusion refused to engage with LifeSci beginning on September 27, 2022. On the contrary, it was LifeSci who went dark from this point on, continuing its refusal to provide additional details regarding the types of transactions their purported clients were proposing before submitting their client&#8217;s unsolicited offer.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">One thing is crystal clear: in the public biopharma markets, LifeSci&#8217;s record is abysmal. LifeSci has demonstrated on multiple occasions that it is ill-equipped to evaluate and identify value-enhancing alternatives or oversee a successful M&amp;A process. Particularly demonstrative of LifeSci&#8217;s penchant for underperforming transactions and destroying stockholder value is their recent experience as both a sponsor and financial advisor on a variety of SPAC merger transactions in the life sciences sector:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The LifeSci-affiliated vehicle, LifeSci Acquisition Corp. (&#8220;LSAC&#8221;)<sup style="vertical-align:top;line-height:120%;">1</sup>, for which David Dobkin served as CFO, merged with Vincerx Pharma and its stock price has dropped from the merger closing price of $19.00 on December 23, 2020 to $0.71 as of December 2, 2022, a <b>decline of approximately 96%.</b>&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The LifeSci-affiliated, LifeSci Acquisition II Corp.,<sup style="vertical-align:top;line-height:120%;">2</sup> for which David Dobkin served as CFO, merged with Science 37 and its stock price has dropped from the merger closing price of $9.01 on October 6, 2021 to $0.60 as of December 2, 2022, a <b>decline of approximately 93%</b>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The LifeSci-affiliated, Petra Acquisition Corp. (&#8220;Petra&#8221;)<sup style="vertical-align:top;line-height:120%;">3</sup>, an entity with past affiliations to LifeSci Capital, David Dobkin (as both a director of Petra and in his capacity as a managing director of LifeSci Capital), and one of its director nominees, Jessica M. Lockett, who served as counsel to Petra, merged with Revelation Biosciences Inc. and its stock price has dropped from the merger closing price of $8.32 on January 10, 2022 to $0.22 as of December 2, 2022, a <b>decline of approximately 97%</b>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img src="ex_453243img001.jpg" style="width:375;height:190;" alt="ex_453243img001.jpg"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>In the aggregate, these three LifeSci-led merger transactions have resulted in stockholder losses exceeding </i></b><b><i><u>$1.3 BILLION</u></i></b><b><i> over the last two years, drastically underperforming the broader life sciences market.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Despite this record of stockholder value destruction, in those same transactions, LifeSci extracted millions of dollars for itself through investment banking fees, advisory fees and a tangled web of additional related party relationships by hiring one or more of LifeSci&#8217;s countless affiliates to act in various other roles, such as financial advisor, underwriter, and administrative services provider. In the quintessential example of LifeSci&#8217;s self-interested investing style, LifeSci Capital is currently suing Revelation seeking to recover more than $5 million in investment banking fees &#8211; an amount that would effectively drain all of Revelation&#8217;s cash reserves &#8211; despite the fact that LifeSci itself held approximately 7% of Revelation&#8217;s outstanding stock at the time the suit was filed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">1</sup><i>&nbsp;Now known as Vincerx Pharma, Inc. (</i>&#8220;<i>Vincerx</i>&#8221;<i>) (NASDAQ: VINC).</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">2</sup><i> Now known as Science 37 Holdings, Inc. (</i>&#8220;<i>Science 37</i>&#8221;<i>) (NASDAQ: SNCE).</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">3</sup>&nbsp;<i>Now known as Revelation Biosciences Inc. (</i>&#8220;<i>Revelation</i>&#8221;<i>) (NASDAQ: REVB).</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In all three of the transactions identified above, the merger parties were purportedly introduced through a combination of Mr. Paul Yook, the chief investment officer of LifeSci&#8217;s venture capital funds, and Mr. Dobkin. In two of those transactions &#8211; Science 37/LSAQ and Revelation/Petra &#8211; in parallel with the SPAC&#8217;s formation and capital raising activities, Mr. Yook&#8217;s funds made pre-merger investments in the private operating companies at valuations significantly below the valuations assigned to the company by LifeSci Capital, in its capacity as a financial advisor on the transactions, and the parties thereto for purposes of the subsequent business combination.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In certain cases, LifeSci also benefitted from sponsor arrangements which allow SPAC sponsors to buy shares for pennies on the dollar and, in many cases, sell those shares at temporarily inflated valuations following a business combination transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LIFESCI PRESENTED AN UNSOLICITED OFFER REPRESENTING APPROXIMATELY HALF OF DIFFUSION</b>&#8217;<b>S CASH POSITION AND HAS REPEATEDLY REFUSED TO ENGAGE WITH OUR BOARD</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If LifeSci were interested in value creation for all stockholders, why haven&#8217;t any of their purported clients joined the strategic review process? Why was LifeSci unwilling to sign a customary non-disclosure agreement that more than 15 participants in the process were willing to sign? Why did LifeSci amend its proxy statement to disclose that <b>Mr. Dobkin, the portfolio manager of LifeSci Master Fund,</b> &#8220;<b>will be entitled to receive certain fees and related compensation in the event that the Company completes a transaction with any of [LifeSci] Capital</b>&#8217;<b>s investment banking clients</b>,&#8221; due to the fact that he also serves as a managing director for LifeSci Capital?</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci, rather than constructively engaging in the Company&#8217;s robust process, has instead chosen to selectively engage with Diffusion offering vague notions of pursuing unidentified potential transactions with unidentified counterparties. Moreover, throughout its interactions with Diffusion, LifeSci has obfuscated and misled Diffusion regarding on whose behalf it was acting, repeatedly insinuating that LifeSci was acting on behalf of &#8220;client-stockholder&#8221; when in fact it was LifeSci itself who was acquiring our stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Following a period of silence after going dark in late September, LifeSci presented an unsolicited offer, on behalf of one if its purported clients, to purchase all of Diffusion&#8217;s outstanding common stock for $6.58 per share, or an aggregate purchase price of approximately $13.4 million, effectively seeking to use Diffusion&#8217;s own cash to buy out Diffusion&#8217;s other stockholders.<sup style="vertical-align:top;line-height:120%;">4</sup> This offer represented an approximate <b>48% discount to our cash position</b> of $25.9 million<sup style="vertical-align:top;line-height:120%;">5</sup> as of September 30, 2022, effectively provided no value for the Company&#8217;s trans sodium crocetinate assets, and offered no opportunity for Diffusion stockholders to participate in potential future upside of the enterprise. This is disturbing if this is the new promise of value creation that LifeSci&#8217;s nominees hold for us as stockholders and contradictory to their own public statements regarding the significant potential value of Diffusion&#8217;s assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">4</sup>&nbsp;<i>Based on 2,039,441 shares outstanding as of November 10, 2022.</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">5</sup>&nbsp;<i>Includes cash equivalents and marketable securities.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">After deliberation and in consultation with its advisors, and in the exercise of its fiduciary duty to protect the interests of <b>ALL</b> Company stockholders, our Board rejected LifeSci&#8217;s offer as woefully inadequate.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In our letter to LifeSci rejecting the offer, the Board encouraged LifeSci to have its client participate in Diffusion&#8217;s strategic review, but LifeSci&#8217;s affiliates once again refused to enter into the customary non-disclosure agreement signed by more than 15 parties. LifeSci then went silent. This unwillingness to negotiate at all raises further questions about the true intent behind LifeSci&#8217;s strategy. Diffusion was particularly surprised when a different investment bank approached Diffusion regarding having this same company join our review process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A few weeks later, in the middle of the strategic review process and in another potentially destructive attempt to take advantage of Diffusion and its stockholders, LifeSci announced on November 17, 2022, the commencement of a proxy contest on its own behalf, nominating a slate of directors for election at our upcoming annual meeting of stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that <b>LifeSci is engaged in another attempt to undertake a conflicted, value-destructive transaction</b> and is using Diffusion&#8217;s annual meeting to <b>cause confusion and</b> <b>disrupt the positive progress </b>made during the strategic review process so far in hopes of achieving an alternative, self-serving outcome.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LIFESCI</b>&#8217;<b>S NOMINEES LACK PUBLIC COMPANY BOARD EXPERIENCE THAT WILL BE CRITICAL TO OVERSEEING A SUCCESSFUL COMPLETION OF THE STRATEGIC REVIEW PROCESS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While LifeSci&#8217;s public company experience is checkered with conflicts of interest and poor results, the public company experience of its director nominees is virtually non-existent. Only two of LifeSci&#8217;s nominees have any experience sitting on public company boards, but that experience does not inspire confidence:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ms. Jessica M. Lockett has served on the board of directors of an ammunition company, Ammo, Inc, since December 2020. In August 2022, one of Ms. Lockett&#8217;s fellow directors launched a proxy contest seeking to replace her on the board with one of his own nominees. Her seat on the board was only assured after Ammo subsequently entered into a settlement agreement with the other director.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. John S. Ziegler MD&#8217;s only previous public company board experience consists of approximately one year serving on the board of directors of LifeSci Acquisition Corp. at a time when it was effectively a shell company. In September 2020, he and his fellow directors approved the value-destroying merger with Vincerx.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, of the six LifeSci nominees, <b>ZERO</b> have held an executive role at a publicly traded pharmaceutical company and <b>three</b> have never worked in the healthcare industry at all. Further, LifeSci has nominated individuals with seemingly no connection to pharmaceutical development, instead involved as consultants and advisors to solar, real estate and technology industries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our board is committed to protecting the interests and maximizing long-term value for <b>ALL </b>Diffusion stockholders. We believe that the election of any directors from LifeSci&#8217;s slate threatens to seriously jeopardize the progress of our strategic review process, and therefore, <b>we strongly urge stockholders to vote the WHITE proxy card in favor of Diffusion</b>&#8217;<b>s highly qualified and experienced nominees</b>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On behalf of the Board of Directors, we thank you for your continued investment in Diffusion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sincerely,</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jane H. Hollingsworth</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>If you have any questions or need assistance in voting your shares, please contact Innisfree M&amp;A Incorporated, Inc., our proxy solicitor, at (877) 456-3402. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies to enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. Diffusion&#8217;s lead product candidate, TSC, is being investigated to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions, including hypoxic solid tumors like GBM. For more information, please visit us at&nbsp;www.diffusionpharma.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including: the timing and potential outcome of the Company&#8217;s ongoing strategic alternative review process; the potential therapeutic value of TSC in cancer and non-cancer indications; anticipated timelines for the initiation, completion, and announcement of data from Study 200-208; the Company&#8217;s ongoing and planned clinical trials; the Company&#8217;s near-term strategic priorities with respect to the development of TSC and otherwise; and the Company&#8217;s anticipated cash runway. The Company may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, the Company&#8217;s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s ongoing strategic alternative review process; the novelty of the Company&#8217;s Oxygenation Trials&#8217; design and endpoints, the relevance of trends observed in those studies to any indication, including hypoxic solid tumors, and the therapeutic value of TSC; the optimal doses and dosing regimens of TSC in connection with the potential treatment of GBM; the Company&#8217;s ability to design, initiate, enroll, execute, and complete its planned studies evaluating TSC, including Study 200-208; the likelihood and timing of regulatory approval of TSC, if any, for the treatment of solid tumors complicated by hypoxia or any other indication, or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration or other regulatory bodies; the impact of global supply chain disruptions on the Company&#8217;s drug product manufacturing capabilities, clinical development program, and associated timelines; the Company&#8217;s ability to identify, evaluate and execute potential business development transactional opportunities, if any; the Company&#8217;s ability to protect and expand its intellectual property portfolio; the Company&#8217;s access to capital resources: general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts</b><br>
<br>
Gladstone Place Partners</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Felipe Ucr&#243;s</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">212-230-5930</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tiberend Strategic Advisors, Inc.&nbsp;<br>
Daniel Kontoh-Boateng/Jonathan Nugent<br>
dboateng@tiberend.com<br>
jnugent@tiberend.com</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Important Additional Information Regarding Proxy Solicitation</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Diffusion intends to file a definitive proxy statement and associated WHITE proxy card with the U.S. Securities and Exchange Commission (the </b>&#8220;<b>SEC</b>&#8221;<b>) in connection with the solicitation of proxies for the Annual Meeting (the </b>&#8220;<b>Proxy Statement</b>&#8221;<b>). Stockholders as of the record date of November 1, 2022 are eligible to vote at the Annual Meeting. Diffusion, its directors and certain of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the Annual Meeting. Information regarding the names of Diffusion</b>&#8217;<b>s directors and executive officers and their respective interests in Diffusion by security holdings or otherwise is set forth in Diffusion</b>&#8217;<b>s proxy statement for the 2021 Annual Meeting of Stockholders, filed with the SEC on April 30, 2021, and the Company</b>&#8217;<b>s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 18, 2022. To the extent holdings of such participants in Diffusion</b>&#8217;<b>s securities have changed since the amounts set forth in the 2021 proxy statement, such changes have been reflected on Statements of Change in Ownership on Form 4 or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC. Details concerning the nominees of Diffusion</b>&#8217;<b>s Board of Directors for election at the Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY</b>&#8217;<b>S DEFINITIVE PROXY STATEMENT AND ACCOMPANYING WHITE PROXY CARD, AND ANY SUPPLEMENTS THERETO, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive Proxy Statement and other relevant documents filed by Diffusion with the SEC free of charge from the SEC</b>&#8217;<b>s website, www.sec.gov., or by directing a request by mail to Diffusion Pharmaceuticals Inc., Attention: Corporate Secretary, at 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, via e-mail to proxyrequests@diffusionpharma.com, or by visiting the investor relations section of Diffusion</b>&#8217;<b>s website, investors.diffusionpharma.com.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dffn-20221205.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/6/2022 2:06:37 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dffn="http://www.dffn.com/20221205" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dffn.com/20221205">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20221205_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20221205_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20221205_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.dffn.com/20221205/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="dffn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>dffn-20221205_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/6/2022 2:06:37 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.dffn.com/20221205/role/statement-document-and-entity-information" xlink:href="dffn-20221205.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.dffn.com/20221205/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dffn-20221205_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/6/2022 2:06:37 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dffn-20221205_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 12/6/2022 2:06:37 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.dffn.com/20221205/role/statement-document-and-entity-information" xlink:href="dffn-20221205.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.dffn.com/20221205/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex_453243img001.jpg
<TEXT>
begin 644 ex_453243img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "^ 7<# 2(  A$! Q$!_\0
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M !FJ/VGQU_T"?#O_ (,9O_C5=/?Y-C,JMM9UV@CL3Q_6HX9/,@1SU(Y^O?\
M6@KE]WF,,/XRQS;^'Q[>?/\ _$5 1X]R<2>& ,\ QW!Q^M=/D49%!)BQQ>,O
M+7-[H ..0+.8C_T;4#6'CEF)'B#1%!.0O]E2''MGSJZ="-@YIV10!SJZ;XLV
M#?XDL-V.=NE'&?;][5=]"\7O(S#QI&@)X5=)CP/IEB?UK7U3Q)HFB#_B9ZK:
M6K=DDE&]OHO4_@*R_P#A+Y[T[=$\.ZK? \B::/[)"1Z[I<,?P4T +_8GB)54
M2^+YV?')73X #^!!_G5=_#>NNS2'QQJR#J0EK;!1^<?'YU(T'C#4#FXU#3-(
MC/1+2$W4H_X&^U?_ !PTT>"=+N"&U>YO]9<'/_$PN6:/_OTNU/\ QV@#&GU'
M3[*1;63X@ZO>7O0PV4<$\A/^Y'"V/QK.N[7Q!<QRWEO>^)K*V12\EUJ^I06<
M2*!RVQ(V8#ZA:[R>XT?PMH\D[+;:?80@9$,80>@4*HY)Z #DUCV^F7GBB[BU
M#7X&M]-C<26>D/C)(Z27'8MW"=%[Y/0 Y[P-H?BW4-475]2\4ZDVC1D-;0GY
M3>=]Q##(C/09 +#G [][=V-M)KT%U%??9M1\@QE%*DRP[L_=/H>A'3)]:ULC
MUK'N[2[_ .$GMM1AB22**RE@.9-IW,\;#MTPA_2@#/D\,Z7<7TTLVHL[WDC$
MQ[U&\ H=H]PT0.>O7\&MX5LMZ00:DZ&(LPA&UMO[R.3 !^Z,Q+P..3TR,56T
M;Q"MPUTLJO-Y9B+&YPS)Y\C8!Q\I",N#CMCWJ1] U>RN9KK39U)<%I89Y@1(
MV4RR/MS&SJI#8^7." *$#(=-\-OI>M),MZC6EHN3OV9Y5LEAC*MAR 0<;:N?
M\(S;7$4[2ZA++;7%TU^ H55$A7"L#CD#@CW )S4D-AJ^;Q7N_P!PZJ(XY7\T
ML/*VLN[C;\W.<'/6L^STSQ%;011/*K1PK%'Y27.U7B"J&4?+\K @_-G!'UX
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M"FI/ \#M::IJCV[P+J5\TT"2(4?R558XRRGD$K'NY_O"MRX^:_MU!^XCN?T
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MJD6"6CE&X_NOESYH_P!G']?KTJ@]M-.A26YNT!X9(PY8CTR>!5M;.0(/W<Q
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MP !@"EJRVXQMIJAL3K)$DJ  .H;CWIEVVVTF<\E8VP?PIMI\BR0?\\I" /\
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MT 6**/PH_"@ IK_<-._"FO\ </% $%20_P 7UJ/\*9)/)!&S1V[S'=]U3[4
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MONGZ5EZ1_P @&P_ZXK_*G?6Q"BN1R\U^I<R/6C(]:**9 9'K5@$8ZU7JP.E
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MNH&8W-D3LVJ-C ;B1@G\,_I3XXM;!_>7-DWRMTC;KV/7ITHL2DD[HE?3;6.
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)\36>\W][/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140008145505568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">DIFFUSION PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Dec.  05,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">000-24477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">300 East Main Street, Suite 201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Charlottesville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">22902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">220-0718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DFFN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>dffn20221205_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dffn-20221205.xsd" xlink:type="simple"/>
    <context id="d20228K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2022-12-05</startDate>
            <endDate>2022-12-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20228K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20228K">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20228K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20228K">2022-12-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20228K">DIFFUSION PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20228K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20228K">000-24477</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20228K">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20228K">300 East Main Street, Suite 201</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20228K">Charlottesville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20228K">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20228K">22902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20228K">434</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20228K">220-0718</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20228K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20228K">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20228K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20228K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20228K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K">DFFN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20228K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MSNJP13Y<&)GFV](5K$%DG)]N.0-;L W@^5I*\W%A=[K%'Q6#_P!02P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( %FOA54'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 6:^%55'#'3/O    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " !9KX55.JJBYT !   \ @  #P
M    @ %F$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 6:^%520>FZ*M
M    ^ $  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ 6:^%5660>9(9 0  SP,  !,
M ( !N!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @   A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dffn20221205_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dffn.com/20221205/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dffn20221205_8k.htm">dffn20221205_8k.htm</File>
    <File>dffn-20221205.xsd</File>
    <File>dffn-20221205_def.xml</File>
    <File>dffn-20221205_lab.xml</File>
    <File>dffn-20221205_pre.xml</File>
    <File>ex_453243.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dffn20221205_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "dffn-20221205_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dffn20221205_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dffn-20221205_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dffn-20221205_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dffn-20221205.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dffn",
   "nsuri": "http://www.dffn.com/20221205",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20221205_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.dffn.com/20221205/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20221205_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.dffn.com/20221205/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-22-028487-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-028487-xbrl.zip
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M&I*PF@%-\-=N ?/>+4C3, N71&I^'7"\-)49TCA9U5_X_ U02P,$%     @
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M$7_7EKT:3Y%P=S[%>2G3,YQ_YRX^&7 FB":1Y9KN9OMCE@N+C36!^2.$P*C
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M9\JF81Y6#LRRO1IKX%/+V_:+W9Z6"O1^ _ ^!?D3G$_I\L@M!FW+TQ+T;J=
ML-<,1B,N)<X$D9YHYHT2$8%HQQC7+G:*W2)IC4(OF#+Q(HS+RB*Y#(HY3(SE
M[ U\1F:NI*WN)F.CG37S!V;Q<#<T<\-U!9,R_OC$?6;%6MDD+0K!V 4%YZ^K
M!&-JGW3''!2:;5H/>:^[,N<F_'HE>L&='Z50P+GU J68O.6>E^^T].O[ZP:C
MJSE3,4G:8%R):ZC)<=\Q#DK_PW'&G*X0C*ZK!7<.J=<!,-/[+P]G;J9MGYC?
MT'=X&0[MQ=-%/R$4  8>4H^P"7/&BM]BL ;JF\FG&K\7FA0L&\%UVTYSL\DD
MV-YZ(H"ZJB$8G8$>_E22C.5]Y+];,YW^*0"07 \#/QVR:-$"Y_S(.MZN+-C>
M/-GR]L=CVSJJ2:*8QT*< /'U#/;1N_;&Z"D0"$$I<& .N]<)J<M $1J&'@A\
M/[%?&U^:<Z@&H4Z44!+:$,)7&BDS6)0!B?+NH*+0PA$/?8PHU?M*5N?/L03?
M>IH=N#EDSA>">Q"P0B( C8Z183^8D#[S@COD"Q8B]\BQ\9$,]-$FPB7 6#'?
M!7ZI %@V&GN*^BP82V]*)+CO<C#5+>,&01]HH$F B06IE)X^ZD*H/TW*!H$'
M@V,[]$TX1G.RNO%5>*J7G]ERUPO ?0QLJL0,)_>=]R4VD:!1+"P:SJ3O8TWP
MHI6<[>ACQ)!.O2=KO_)IGGVB'^\3"?IT<#\>>5KNKA\$7I_"VL+D)VD]_YO@
MX.#Z&+R/_3C\D[@@)T>52FV]M%3,HOC$T4NR*)X5\"8]+1*F-B,[8X!8Q3Z(
M96!A,Q#W />L(](\[Q"[;!:AXG9Z*-]%96.BT@W D (\_)L+4-6P0EXL)X<[
M*R?S*9%1/*?[0F)5J&'9*3G)[)3/I*1B%J.:WP7E;RXHUX*A/<%#D?I$#GHK
MXFHPP"ABQPT+3,UP4G-[U,)8%=>P]_KO5A.?J.YW ?HN0&D!:DLY9N+O+49E
M9E3VG-7$**Z[G6*TN0@SY<Y&(1\3$#2&>0?RM(:*0T!@Y^Y$?)O:UXDH,Y(V
M>'XJ?J0K5(D$3\J=/8P/4/4]"C%^]%/<]/?,?8)_WM5(GG9+**K8Q>-OFXG-
MA4L/+\5$I^Z<(7$\*N7#ZB2>:S]0*AAIID1<6&.J=@63S@G7H"3=C>;;K%#,
MCJYEBC?/)D%U"K$['?4#;^^Q?/LS,"G:EMXI)EW&I\<TE%BBJ$'3W TY/)FK
MH[4V9)Z!EY%L)>SRV""'6]O&S/42]['6GUIV7TMTH8ZN1( [MH'S9=%AV"<A
M%>26>F-&_F463=,B(=X[&NI#6AN5_MUD=ZP.(FU0J)^=GU^NYY0]NX+8)3XN
M>L2H*NYOB">03CR^Z#SM9:-[UOCW(K-)DX8<+VU>4/&%J>=P ;\!;U[,)SSM
MU]N^BWXVP\NNCMZ$@!I?0#,S?21M88> 2T)] DXZ=G)#;D1PIX;HKH>X:T E
M<=F ^]&!X"BE:AXDGN1"/C6Z4U$F>[@1]?9'Z_"HAIMUIE7#?45,LB9-N3Y8
M'.+!8MPRBB( NV_8.3WG7=M8,@3&!O->4H,47\]MH&6KWLI?P8A/2-:Z/Y\U
MX(W.<R0T?M D-B,*'XMU7^EZM0</R!UN9><*,;^WPS<$$64>Q'D@HGZ@H[ZQ
M9+H6$!'O(^*K.+B.!*/KNKAP>BQOBH/?<1@:Q=V'24*)8+=<0CL0?.H[F#.F
MCGX; 5;&]R.X5+@RVD%TEX6<Y3TZ"SG3,EPD3\?D4W_&^'KV=7X,33K(>E^X
M_O#+Q_QT6=1![*?JJ#5^$AMY>%2H+_1UWNO,.LN[!)0:8*'M<&  S.X_Q-B;
M7'^X_'RQ,(OL1_KVT77C0\OXI=-J?#0:Y[U6ITJH=T>G<O'^4&:VR?4D>ZWK
M2?,K1S,6_'J6SP+DXY,9T+MJ?L)WW#S$@L<P1.XII<=R961I6@XG\PUUU#V%
MI-B('!<A0/@*F]&O7VDGHX7W^>0KM[I7/EF\.[A/SOA@,-:'Y*\AQAI1AXVU
M7R])VW>*X&[),6A,"LH3C_H)4-T4U#7U?4 ^)K^TOL1:^!8:U)\4@* 4.FZ!
MOI$E,<P;!AX(F2R2!LA1.#O=D>T473NE($*' 6%1&'1 T9\:\CY7Y.2D:,&X
M;G3B)+F6$%<%9P\,S^S5%\57O(HQ].>@AP<GQ>B\<X+M8]NRYA _GYE%?7@7
M\]M2<S)F[6O'/9YE=-^][&R?(Y_\"&OB8[/'1?OHT*J4CT[,X\H)Q.%IFXWU
M,A9[MO?RM%L$EOD"B6&,'J*U3"_EQFF(SJ%^Q<'VDV_,O&67VYET! _1Z\TG
M?O4CZ"/NNA[+8"'!_:-\R+0]R6G[E)/P+X)'M$Q;"H%\[%(2O5J*3?ZH')3M
M2AG?0C93.1@9&]"%H(ZJLDC0HBU2L-6=R%;O)X[!_9<1T&>ZU+ FG!9YNJ-8
MLLS*+D&I&0 ]Y)I"J-Q&90.0P:L?9U11?>F2["$Z7 RZ,6@'-PW=OK9^*27!
MMU(2-W[5Q?9NCG^3H!ACUY6#XJ7OU-B9J#8O1-UQ5W/9&\3:'RX;O<^=U5YB
MMAM3S1']]+FI\F%TAB:558N2?G^-N8C#C=7RY/L8\-&1S@+NYV4.W;$W)0X=
M8[9/9\RC>QDX9)\1"<1"01"]"J3/AM0;8%R('>ES.G$%C!C'/K31W8$+/ P$
M\,+=FK!Q:\*/[/&XK"+YJCS2HR%'/-(!:JS4[P7<&X95!-*"\*$S8Y-($]]+
M7ZU\0*>@WP+E5G-<G%S[#.H2& B$V8M6HGR<FL-FI[#B.WY6.*1GV?-)X.\;
MG<4Z#N46 &<EAI9?#A0KD7?P4VH_?PL)_ [(UP[(>'R]KY",ZP=W@H;HU^+G
M'*%+T1J=8]D&_FX_8/,8GD;O4B=_:_&\G.(-$XRNP;-LP!7JOT"KTQ)V^%R"
ML^*1KY>R!L_(NY(L)9ZQ9N!OW/,X'9$6;D^]$BG^;G96) ^/[56WWAGZ#M&_
M,43UB>GMQVCT#Y9X!%^O*9E'WM(1F)AFLD>/:1_!%!73W<7O-IS/?:Z?+[ '
MOSRO_JG1[1GS1';N\;%G/1:6$ &_Q N*_PQ._?]02P,$%     @ 6:^%59B*
MM(JD+0  ^=(   T   !E>%\T-3,R-#,N:'1M[7UI<]O&EO;GR:_H\;W))%4@
M+<EVO,CQ#$U1-A-*U)"T<S-3;[T% DVR8Q! L$AB?OV<I3> I.PL3B)'MUPW
M(HFEE[.?YYQ^OJK6R8OG*QG&+S[[M^>5JA+Y0E[__X>/'AP]?-"%7Y_?YR\_
M^S?X_=\['?%*IK((*QF+^4;,5G4:R^(D6TMQD155F(B..#RZ__7]HX.C(_CK
MV<.#9T>'HG<F.IT7S]>R"D6T"HM25M_<JZM%Y\D]_6T:KN4W]Q99L0ZK3BPK
M&54J2^^)*$LKF<+5E4QDOLI2^4V:W7OQV?/[/.CG\RS>B++:)'1[6G5*];-\
M=GB05\?T<1&N5;)Y]A\SM9:E.)=78I*MP_0_CO,PCE6Z?':@4M$]5.DQ/C56
ME^:5,E95.*?'ADDI[XDXK,).F.?)ILI@/.:+NLHZ^3*MU]_<*ZNP,-_'JLR3
M<$/?'^KO<$ \T=9HO-]Q^' 'C%]_"4_0TPOU-WDA%^KZFWOZ([VU\9ZR7O@7
M5/(:=D8MTV_N13BQXMZ++])YF1\_OP_S??'99\]SLX+KL%BJ])DXR*\%+J'
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M/N-:N^"\8=5DXLH-36T_#<WU[J6> 7J 8,XQ2!T-/.H%%M!(<?KN5IP% \.
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M0,@1;.NJ6B<O_@]02P$"% ,4    " !9KX55^0WE]'@#   O#@  $0
M        @ $     9&9F;BTR,#(R,3(P-2YX<V102P$"% ,4    " !9KX55
M)4R%(-P$  !1+0  %0              @ &G P  9&9F;BTR,#(R,3(P-5]D
M968N>&UL4$L! A0#%     @ 6:^%5=9N"%+[!0  JSP  !4
M ( !M@@  &1F9FXM,C R,C$R,#5?;&%B+GAM;%!+ 0(4 Q0    ( %FOA56>
M(*+5=@0  .4M   5              "  >0.  !D9F9N+3(P,C(Q,C U7W!R
M92YX;6Q02P$"% ,4    " !9KX55=3)SU5H/  "F;0  $P
M@ &-$P  9&9F;C(P,C(Q,C U7SAK+FAT;5!+ 0(4 Q0    ( %FOA568BK2*
MI"T  /G2   -              "  1@C  !E>%\T-3,R-#,N:'1M4$L%!@
0   &  8 A $  .=0      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
